Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 10, 2025 16:30 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
January 10, 2025 16:18 ET | Source: Lowey Dannenberg, P.C.

Lowey Dannenberg Notifies Dentsply Sirona Inc. (“Dentsply Sirona,” “Dentsply,” or the “Company”) (NASDAQ: XRAY) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against...
January 10, 2025 11:00 ET | Source: Innosphere

Numiera Therapeutics Announces Orphan Drug Designation and Matching Funds from the State of Colorado to Advance Innovative Brain Cancer Treatment

Fort Collins, Colorado, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Numiera Therapeutics, an Innosphere client company and pharmaceutical pioneer in small-molecule drugs for oncology, is proud to announce two...
January 10, 2025 11:00 ET | Source: Kirby McInerney LLP

HUMA INVESTOR ALERT: Kirby McInerney LLP Reminds Humacyte, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP notifies investors of the approaching January 17, 2025, deadline to seek the role of lead plaintiff in a federal...
January 10, 2025 10:25 ET | Source: Microbot Medical Inc.

Microbot Medical Closes $8.6 Million Registered Direct Offering

BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under...
January 10, 2025 09:37 ET | Source: Faruqi & Faruqi LLP

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DENTSPLY SIRONA

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Dentsply To Contact Him Directly To Discuss Their Options ...
January 10, 2025 09:26 ET | Source: Y-mAbs Therapeutics, Inc.

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data...
January 10, 2025 09:16 ET | Source: Faruqi & Faruqi LLP

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If...
January 10, 2025 09:00 ET | Source: Disc Medicine Inc

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA...
January 10, 2025 08:59 ET | Source: Faruqi & Faruqi LLP

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Applied Therapeutics To Contact Him Directly To Discuss Their...
January 10, 2025 08:30 ET | Source: Teva Pharmaceutical Industries Ltd; Samsung Bioepis Co., Ltd.

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in...
January 10, 2025 08:30 ET | Source: InflammX Therapeutics, Inc.

InflammX Therapeutics Announces Option Agreement with Bausch + Lomb

TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant...
January 10, 2025 08:30 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
January 10, 2025 08:30 ET | Source: Achieve Life Sciences

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and...
January 10, 2025 08:25 ET | Source: Introspective Market Research

Ablation Devices Market Projected To Reach USD 24.98 Billion by 2032, Growing at a CAGR of 11.25% From 2024-2032 | Introspective Market Research

Portland, Oregon, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Introspective Market Research is pleased to announce the publication of its latest report, Ablation Devices Market. This in-depth analysis shows...
January 10, 2025 08:00 ET | Source: Restem

RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025

MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today...
January 10, 2025 08:00 ET | Source: Palvella Therapeutics Inc.

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

Publication reports 100% of participants were either “Much Improved” or “Very Much Improved” as rated by the Clinician Global Impression of Change following 12-weeks of QTORIN™ rapamycin FDA...
January 10, 2025 08:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
January 10, 2025 08:00 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
January 10, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter...
January 10, 2025 08:00 ET | Source: Cargo Therapeutics, Inc.

CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025

CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
January 10, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical...
January 10, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in January-February

8th Sachs Annual Neuroscience Innovation Forum14th Annual LifeSci Advisors Corporate Access EventInvest Securities BioMed Forum 2025MidCap Events Frankfurt 2025Bio-Neuroscience 2025 MADRID and...
January 10, 2025 07:35 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
January 10, 2025 07:33 ET | Source: Research and Markets

Membrane Chromatography Industry to Generate Revenues of $1.66 Billion by 2035 - Market Analysis of Revenue & Shares by Product, Technique, End User and Region

Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Membrane Chromatography Market by Product, by Technique, by End User, and by Region" report has been added to ResearchAndMarkets.com's offering. This...
January 10, 2025 07:30 ET | Source: Royalty Pharma plc

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion;...
January 10, 2025 07:30 ET | Source: Tourmaline Bio, Inc.

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

Paul M. Ridker, MD, MPH, has joined Tourmaline’s Cardiovascular Scientific Advisory Board (CV SAB).
January 10, 2025 07:15 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

-- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of...
January 10, 2025 07:05 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data...
January 10, 2025 07:01 ET | Source: Invivyd

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as...
January 10, 2025 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025— —Company achieved operating profit in...
January 10, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will...
January 10, 2025 07:00 ET | Source: GH Research PLC

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8Primary endpoint...
January 10, 2025 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
January 10, 2025 07:00 ET | Source: iTeos Therapeutics Inc.

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC ...
January 10, 2025 07:00 ET | Source: Passage Bio

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating...
January 10, 2025 07:00 ET | Source: Future Market Insights Global and Consulting Pvt. Ltd.

Global Biologics Market to Reach USD 1,077.2 Billion by 2035, Growing at a CAGR of 9.1% from 2025-2035 | Future Market Insights Inc.

NEWARK, Del, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The global biologics market is projected to witness substantial growth, with an estimated worth of USD 450.2 billion in 2025, reaching USD 1,077.2...
January 10, 2025 07:00 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione Meaningful Improvements...
January 10, 2025 07:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company’s Response to a Wells Notice...
January 10, 2025 07:00 ET | Source: Bio-Path Holdings, Inc.

Bio-Path Holdings Provides 2025 Clinical and Operational Update

Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path...
January 10, 2025 06:30 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust...
January 10, 2025 06:28 ET | Source: Research and Markets

Digital Breast Tomosynthesis Market to Cross $12.3 Billion in Revenues by 2035, Dominated by Philips Healthcare, Medtronic, GE Healthcare, Honeywell Life Sciences, and Abbott Laboratories

Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Digital Breast Tomosynthesis Market by Component, by Technology, by End-User, and by Region" report has been added to ResearchAndMarkets.com's...
January 10, 2025 06:02 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
January 09, 2025 22:12 ET | Source: The Rosen Law Firm PA

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLT

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between...
January 09, 2025 19:42 ET | Source: Kessler Topaz Meltzer & Check LLP

Class Action Reminder for NASDAQ: XRAY: Kessler Topaz Meltzer & Check, LLP Reminds DENTSPLY SIRONA Inc. Investors of Securities Fraud Class Action Lawsuit

RADNOR, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the...
January 09, 2025 17:05 ET | Source: Theratechnologies

Theratechnologies fait le point sur l’approvisionnement d’EGRIFTA SV(MD)

MONTRÉAL, 09 janv. 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
January 09, 2025 17:05 ET | Source: Theratechnologies

Theratechnologies Provides Update on EGRIFTA SV® Supply

MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
January 09, 2025 16:05 ET | Source: ImmuCell Corporation

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024

PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets...
January 09, 2025 16:00 ET | Source: Mural Oncology, Inc.

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary...
January 09, 2025 16:00 ET | Source: Bronstein, Gewirtz & Grossman, LLC

XRAY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Dentsply Sirona Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...